

# Jacques Turgeon BPharm

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6213706/publications.pdf>

Version: 2024-02-01

84  
papers

2,470  
citations

257450

24  
h-index

214800

47  
g-index

85  
all docs

85  
docs citations

85  
times ranked

2538  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Pharmacogenomics in Reducing the Risk of Drug-Related Iatrogenesis. <i>Current Pharmacology Reports</i> , 2022, 8, 79.	3.0	1
2	Exploring the Association of the COVID-19 Pandemic on Employee Sleep Quality at a Healthcare Technology and Services Organization. <i>Covid</i> , 2022, 2, 168-174.	1.5	0
3	Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report. <i>Medicina (Lithuania)</i> , 2022, 58, 438.	2.0	1
4	Mitigating Benzodiazepine Dependence and the Risk of Drug-Induced QTc Prolongation in the Treatment of Gastroparesis: A Case Report. <i>Medicina (Lithuania)</i> , 2022, 58, 409.	2.0	0
5	Evaluating the Impact of Medication Risk Mitigation Services in Medically Complex Older Adults. <i>Healthcare (Switzerland)</i> , 2022, 10, 551.	2.0	2
6	Assessing the Impact of an Advanced Clinical Decision Support System on Medication Safety and Hospital Readmissions in an Innovative Transitional Care Model: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2070.	2.4	0
7	Pharmacogenomics and Drug-Induced Phenoconversion Informed Medication Safety Review in the Management of Pain Control and Quality of Life: A Case Report. <i>Journal of Personalized Medicine</i> , 2022, 12, 974.	2.5	2
8	Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. <i>Clinical and Translational Science</i> , 2021, 14, 20-28.	3.1	41
9	Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. <i>Pharmaceutics</i> , 2021, 13, 148.	4.5	31
10	Precision Medicine: Applied Concepts of Pharmacogenomics in Patients with Various Diseases and Polypharmacy. <i>Pharmaceutics</i> , 2021, 13, 197.	4.5	2
11	Longitudinal Association of a Medication Risk Score With Mortality Among Ambulatory Patients Acquired Through Electronic Health Record Data. <i>Journal of Patient Safety</i> , 2021, 17, 249-255.	1.7	18
12	Disease-Induced Modulation of Drug Transporters at the Blood-Brain Barrier Level. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3742.	4.1	21
13	Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4967.	4.1	33
14	Assessment of Glycosylated Hemoglobin Outcomes Following an Enhanced Medication Therapy Management Service via Telehealth. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 6560.	2.6	2
15	Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation study. <i>Clinical and Translational Science</i> , 2021, 14, 1799-1809.	3.1	4
16	Tabula Rasa HealthCare company profile: involvement in pharmacogenomic and personalized medicine research. <i>Pharmacogenomics</i> , 2021, 22, 731-735.	1.3	0
17	Classification and Assessment of Medication Risk in the Elderly (CARE): Use of a Medication Risk Score to Inform Patients' Readmission Likelihood after Hospital Discharge. <i>Journal of Clinical Medicine</i> , 2021, 10, 3947.	2.4	6
18	Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6-Mediated Drug-Drug Interactions on Tramadol and O-Desmethyltramadol Exposures via Allosteric and Competitive Inhibition. <i>Journal of Clinical Pharmacology</i> , 2021, , .	2.0	6

#	ARTICLE	IF	CITATIONS
19	Medication-Related Problems Identified by Pharmacists in an Enhanced Medication Therapy Management Model. <i>American Journal of Managed Care</i> , 2021, 27, S292-S299.	1.1	9
20	Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism. <i>Pharmaceutics</i> , 2021, 13, 1466.	4.5	11
21	Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 955.	2.0	2
22	Association of the MedWise Risk Score With Health Care Outcomes. <i>American Journal of Managed Care</i> , 2021, 27, S280-S291.	1.1	10
23	Health Outcomes From an Innovative Enhanced Medication Therapy Management Model. <i>American Journal of Managed Care</i> , 2021, 27, S300-S308.	1.1	3
24	Cannabis Dopaminergic Effects Induce Hallucinations in a Patient with Parkinson's Disease. <i>Medicina (Lithuania)</i> , 2021, 57, 1107.	2.0	3
25	Use of Drug Claims Data and a Medication Risk Score to Assess the Impact of CYP2D6 Drug Interactions among Opioid Users on Healthcare Costs. <i>Journal of Personalized Medicine</i> , 2021, 11, 1174.	2.5	4
26	Determination of CYP450 Expression Levels in the Human Small Intestine by Mass Spectrometry-Based Targeted Proteomics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12791.	4.1	8
27	Letter to the Editor: Geriatric emergency department revisits after discharge with Potentially Inappropriate Medications: A retrospective cohort study. <i>American Journal of Emergency Medicine</i> , 2021, , .	1.6	0
28	Illustrative and historic cases of phenoconversion... <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 13328-13335.	0.0	0
29	Opioids, Polypharmacy, and Drug Interactions: A Technological Paradigm Shift Is Needed to Ameliorate the Ongoing Opioid Epidemic. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 154.	1.6	10
30	Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. <i>Pharmaceutics</i> , 2020, 12, 846.	4.5	83
31	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2591.	2.4	17
32	Effectiveness of an Advanced Clinical Decision Support System on Clinical Decision-Making Skills in a Call Center Medication Therapy Management Pharmacy Setting: A Pilot Study. <i>Pharmacy (Basel)</i> , 2020, 8, 105.	1.0	10
33	ACE2 as a Therapeutic Target for COVID-19; Its Role in Infectious Processes and Regulation by Modulators of the RAAS System. <i>Journal of Clinical Medicine</i> , 2020, 9, 2096.	2.4	27
34	Precision medication: An illustrative case series guiding the clinical application of multi-drug interactions and pharmacogenomics. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 305-312.	0.5	8
35	Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics Are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 63.	1.6	7
36	Association of a Novel Medication Risk Score with Adverse Drug Events and Other Pertinent Outcomes Among Participants of the Programs of All-Inclusive Care for the Elderly. <i>Pharmacy (Basel)</i> , 2020, 8, 105.	1.0	10

#	ARTICLE	IF	CITATIONS
37	A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3257.	4.1	8
38	Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Pharmaceutics</i> , 2019, 11, 440.	4.5	15
39	Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS/MS-based targeted proteomics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 173, 96-107.	2.8	11
40	Modulation of CYP450 Activities in Patients With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1280-1289.	4.7	65
41	Use of 4β-Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 831-840.	4.7	21
42	Activity and mRNA expression levels of selected cytochromes P450 in various sections of the human small intestine. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1367-1377.	2.4	22
43	Implementation of a pharmacist-led pharmacogenomics service for the Program of All-Inclusive Care for the Elderly (PHARM-GENOME-PACE). <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 281-289.e1.	1.5	38
44	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <i>Clinical Cardiology</i> , 2018, 41, 576-585.	1.8	19
45	Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study. <i>BMJ Open</i> , 2018, 8, e020922.	1.9	8
46	Effects of a Series of Acidic Drugs on L-Lactic Acid Transport by the Monocarboxylate Transporters MCT1 and MCT4. <i>Current Pharmaceutical Biotechnology</i> , 2018, 18, 1141-1150.	1.6	6
47	Medication Risk Mitigation. <i>Clinics in Geriatric Medicine</i> , 2017, 33, 257-281.	2.6	14
48	Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1040, 144-158.	2.3	23
49	The Dangers of Polypharmacy in Elderly Patients. <i>JAMA Internal Medicine</i> , 2017, 177, 1544.	5.1	22
50	Implementation of a Standardized Medication Therapy Management Plus Approach within Primary Care. <i>Journal of the American Board of Family Medicine</i> , 2017, 30, 701-714.	1.5	23
51	Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. <i>Pharmaceutics</i> , 2017, 9, 40.	4.5	20
52	Study of Statin- and Loratadine-Induced Muscle Pain Mechanisms Using Human Skeletal Muscle Cells. <i>Pharmaceutics</i> , 2017, 9, 42.	4.5	3
53	Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 414-418.	2.0	4
54	Clinical decision support systems: great promises for better management of patients' drug therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 993-995.	3.3	14

#	ARTICLE	IF	CITATIONS
55	Development of a sensitive method for the determination of oxycodone and its major metabolites noroxycodone and oxymorphone in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1008, 174-180.	2.3	13
56	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 428-436.	2.0	64
57	Effects of $\beta$ -Blockers and Tricyclic Antidepressants on the Activity of Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 552-558.	2.5	6
58	Prevalence and Risk of Potential Cytochrome P450-Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy. <i>Annals of Pharmacotherapy</i> , 2013, 47, 324-332.	1.9	143
59	Factors Predisposing to Coma and Delirium. <i>Critical Care Medicine</i> , 2013, 41, 999-1008.	0.9	92
60	Domperidone and Sudden Cardiac Death. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 215-217.	1.9	24
61	The role of MCT1 and MCT4 in drug-induced muscle disorders. <i>FASEB Journal</i> , 2013, 27, 674.1.	0.5	2
62	Combined Administration of Quinidine and Propafenone for Atrial Fibrillation: The CAQ-PAF Study. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 171-179.	2.0	8
63	QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 599-608.	1.9	47
64	Rosuvastatin Blocks hERG Current and Prolongs Cardiac Repolarization. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 868-878.	3.3	13
65	Detection and Prevention of Drug-Drug Interactions in the Hospitalized Elderly: Utility of New Cytochrome P450-Based Software. <i>American Journal of Geriatric Pharmacotherapy</i> , 2011, 9, 461-470.	3.0	48
66	Lengthening of Cardiac Repolarization in Isolated Guinea Pigs Hearts by Sequential or Concomitant Administration of Two IKr Blockers. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 2469-2481.	3.3	16
67	Metabolic Activity and mRNA Levels of Human Cardiac CYP450s Involved in Drug Metabolism. <i>PLoS ONE</i> , 2010, 5, e15666.	2.5	60
68	Drug-induced long QT syndrome and torsade de pointes. <i>Canadian Journal of Cardiology</i> , 2005, 21, 857-64.	1.7	25
69	Effect of a low-glycaemic index-low-fat-high protein diet on the atherogenic metabolic risk profile of abdominally obese men. <i>British Journal of Nutrition</i> , 2001, 86, 557-568.	2.3	125
70	Study of the drug-drug interaction between simvastatin and cisapride in man. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 229-234.	1.9	18
71	Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 466-477.	4.7	130
72	Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings*1. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 44-57.	4.7	36

#	ARTICLE	IF	CITATIONS
73	Domperidone Should Not Be Considered a No-Risk Alternative to Cisapride in the Treatment of Gastrointestinal Motility Disorders. <i>Circulation</i> , 2000, 102, 1883-1885.	1.6	160
74	Concomitant Block of the Rapid (IKr) and Slow (IKs) Components of the Delayed Rectifier Potassium Current is Associated With Additional Drug Effects on Lengthening of Cardiac Repolarization. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999, 4, 143-150.	2.0	15
75	Droperidol Lengthens Cardiac Repolarization due to Block of the Rapid Component of the Delayed Rectifier Potassium Current. <i>Journal of Cardiovascular Electrophysiology</i> , 1999, 10, 1597-1604.	1.7	130
76	CYP2D6 Mutations and Therapeutic Outcome in Schizophrenic Patients. <i>Pharmacotherapy</i> , 1999, 19, 1057-1063.	2.6	18
77	Clinical Pharmacokinetics of Mexiletine. <i>Clinical Pharmacokinetics</i> , 1999, 37, 361-384.	3.5	58
78	Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. <i>Pharmacogenetics and Genomics</i> , 1999, 9, 683-696.	1.5	17
79	Block of the Rapid Component of the Delayed Rectifier Potassium Current by the Prokinetic Agent Cisapride Underlies Drug-Related Lengthening of the QT Interval. <i>Circulation</i> , 1998, 97, 204-210.	1.6	173
80	Role of CYP2D6 in the N-hydroxylation of procainamide. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 381-390.	5.7	32
81	The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 512-521.	4.7	125
82	Erythromycin Blocks the Rapid Component of the Delayed Rectifier Potassium Current and Lengthens Repolarization of Guinea Pig Ventricular Myocytes. <i>Circulation</i> , 1995, 91, 3010-3016.	1.6	85
83	Angiotensin II modulates the delayed rectifier potassium current of guinea pig ventricular myocytes. <i>Pflugers Archiv European Journal of Physiology</i> , 1994, 427, 553-555.	2.8	52
84	The Role of Ethnicity in Managing Cardiovascular Patients. , 0, , 33-46.		0